Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CFO Charles N. York II acquired 6,500 shares of the business’s stock in a transaction on Friday, December 1st. The shares were bought at an average cost of $4.59 per share, with a total value of $29,835.00. Following the completion of the acquisition, the chief financial officer now owns 10,828 shares of the company’s stock, valued at approximately $49,700.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Aeglea Bio Therapeutics Inc (NASDAQ AGLE) traded up $0.03 during mid-day trading on Thursday, reaching $4.91. The company had a trading volume of 62,815 shares, compared to its average volume of 65,900. Aeglea Bio Therapeutics Inc has a 1 year low of $2.81 and a 1 year high of $8.14.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.07. The company had revenue of $1.26 million during the quarter. Aeglea Bio Therapeutics had a negative return on equity of 44.05% and a negative net margin of 527.99%. analysts anticipate that Aeglea Bio Therapeutics Inc will post -1.97 EPS for the current year.
Separately, Zacks Investment Research upgraded Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 target price for the company in a research note on Friday, November 10th.
COPYRIGHT VIOLATION WARNING: “Charles N. York II Purchases 6,500 Shares of Aeglea Bio Therapeutics Inc (AGLE) Stock” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3080512/charles-n-york-ii-purchases-6500-shares-of-aeglea-bio-therapeutics-inc-agle-stock.html.
About Aeglea Bio Therapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.